(Q36422375)

14 August 2017

Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations (English)

1 reference

14 August 2017

phase I clinical trial

0 references

1 reference

Itoh K

1

1 reference

14 August 2017

Sasaki Y

2

1 reference

14 August 2017

Fujii H

3

1 reference

14 August 2017

Ohtsu T

4

1 reference

14 August 2017

Wakita H

5

1 reference

14 August 2017

Igarashi T

6

1 reference

14 August 2017

Abe K

7

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

76

1 reference

14 August 2017

1

1 reference

14 August 2017

107-113

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1997.344

14 August 2017

0 references

cites work

Factors affecting quality of informed consent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Responses and toxic deaths in phase I clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Choice of starting dose and escalation for phase I studies of antitumor agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Patient motivation and informed consent in a phase I study of an anticancer agent

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Informing patients about phase I trials--how should it be done?

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Perceptions of cancer patients and their physicians involved in phase I trials

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Informed consent -- why are its goals imperfectly realized?

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Informed consent for investigational chemotherapy: patients' and physicians' perceptions

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

On the nature and ethics of phase I clinical trials of cancer chemotherapies

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2223787

Do-not-resuscitate orders at a teaching hospital in Japan

4 December 2018

1 reference

12 December 2020

Therapeutic response in phase I trials of antineoplastic agents

1 reference

12 December 2020

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

1 reference

12 December 2020

Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan

1 reference

12 December 2020

Is informed consent essential for all chemotherapy studies?

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1997.344

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference

14 August 2017

1 reference